12/13/22 8:00 AMNasdaq : IMMX clinical triallow floatImmix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialIn December 2022, the 15 th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110 combinationRHEA-AIneutral
12/12/22 8:00 AMNasdaq : IMMX clinical triallow floatImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient DosingImmix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today announced that it has completedRHEA-AIneutral
11/11/22 8:00 AMNasdaq : IMMX clinical trialfda approvallow floatImmix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review VoucherEnrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report on drugRHEA-AIvery positive
10/25/22 8:00 AMNasdaq : IMMX conferencesclinical triallow floatImmix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical companyRHEA-AIvery positive
10/18/22 8:00 AMNasdaq : IMMX clinical triallow floatImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead SiteCalifornia Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeksRHEA-AIneutral
09/07/22 12:05 PMNasdaq : IMMX clinical triallow floatImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical TrialsScaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying thisRHEA-AIneutral
05/20/22 8:47 AMNasdaq : IMMX low floatImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice StudyOne cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs IMX-110 is in clinicalRHEA-AIvery positive
05/09/22 8:00 AMNasdaq : IMMX buybacklow floatImmix Biopharma Announces Share Repurchase ProgramImmix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directorsRHEA-AIneutral
04/05/22 9:30 AMNasdaq : IMMX low floatImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022RHEA-AIneutral
03/07/22 8:00 AMNasdaq : IMMX low floatImmix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcement is available atRHEA-AIneutral